The Oncology Platform constitutes a radically innovative care model for the cancer patient, eliminating the traditional barriers between the different departments, making the patient the center of a flexible, dynamic, open and horizontal structure, more agile and efficient than the traditional, without waiting lists and integrated by the different specialties with the patient and his family. The professionals maintain a permanent communication with each other to attend to all the patient's needs.

In addition, this organization allows the rapid implementation of advanced and strategic interdisciplinary programs that require high coordination between different specialists.

The TEDECA Foundation is the instrument that has provided the Oncology Platform and the Hospital Quirónsalud Torrevieja with many of the latest technological advances such as the Molecular Biology Laboratory, cancer immunology techniques, Radiopharmacy, Tissue Bank, Robotic Surgery, etc. .

The Oncology Platform is made up of specialists from different healthcare areas such as Medical Oncology, Radiation Oncology, Oncological Surgery, Psycho-oncology, Nuclear and Radiofísica Medicine, Immunology and Cell Therapy, Pathological and Molecular Anatomy, Genetic Counseling Unit, Personalized Pharmacotherapy Unit and Molecular Genetics and Genomics.

If you want more information, visit our website link opens in a popup window


The research projects are closely related to the unique programs developed by the Oncology Platform at the Hospital Quirónsalud Torrevieja (see website www.fundaciontedeca.orgThis link opens in a popup window).

Unique welfare projects

a) Genomic Area: Genomic expression study and massive sequencing (DNA and RNA) of the latest generation. Search of genomic profiles and signatures for the diagnostic, prognostic and therapeutic study based on the drug resistance / sensitivity profile.

b) Immunotherapy Area: Development of autologous vaccines (TIL, dendritic cells ...) in the White Room. Specific measurement of antitumor immunity.

c) Nuclear Medicine Area: Generation of new isotopic markers, production and distribution of markers for distribution to PET units in the environment. Pharmacological studies. Cyclotron. Radioisotope treatment of cancer.

d) Radiation Therapy Area: IGRT. Re-irradiation of recurrences in treated field and in complex anatomical areas. Radiosurgery Stero-atoxic radiotherapy ("TrueBeam").

Proton Accelerator for the ablative treatment of delicate specific lesions (eye tumors, SNC).

e) Surgery Area: Development of robotic surgery for microdissection and tumor resection. Isolated limb perfusion. Hepatic isolated perfusion.

f) Personalized Pharmacotherapy Area: Pharmacokinetic analysis (mass spectrometry) for personalized optimization of oncological treatment in conventional chemotherapy and TKIs. Study of possible drug interactions in cancer therapy.

g) Medical Oncology Area: Therapeutic intensification with intraarterial and supraselective regional therapies. Interleukin-2 high dose intravenous bolus.

h) Psycho-oncology area: Early and continuous psychological intervention for cancer patients and their families. Zahorí Project.

Research Projects (current):

a) Molecular profile of cancer based on expression Microarrays for the selection of the best treatment in:

i. Advanced and refractory cancer.

ii. Neoadyuvancia in breast cancer "Triple negativo".

b) Development of an analysis methodology for monoclonal antibodies in human serum (part I). Novel approximation for its quantification. Project financed by IMPIVA (Institute of Small and Medium-sized Valencian Companies). Year: 2010. Endowment 38,964 euros.

c) Development of an analysis methodology for monoclonal antibodies in human serum (part II). Novel approximation for its quantification. Project financed by IMPIVA (Institute of Small and Medium-sized Valencian Companies). Year: 2011. Provision 54,090 euros.

d) Characterization of the relationship between exposure to intraperitoneal oxaliplatin with hyperthermia and its haematological toxicity and efficacy in patients with peritoneal carcinomatosis undergoing surgery. Project funded by the Ministry of Health. I.P: Dr. Belén Valenzuela Year: 2011. Endowment: 6,000 euros.

e) Prospective evaluation of the efficacy and safety of lapatinib after personalization of its dosage through pharmacotherapeutic monitoring of plasma levels. Project financed by the Mutua Madrileña. Year: 2013. Endowment: 45,000 euros.

f) Study of the technique "One Step" (tumor resection, radiotherapy, reconstruction in the same surgical act) for localized breast cancer.

g) Search for meaning in the experience of cancer. Adaptation of "Dignity Therapy" through the "Zahorí Project".

h) Early psychological intervention in patients with thyroid cancer.

i) Activation of antitumor cytotoxic lymphocytes, by fusion of dendritic cells and antologous tumor cells (Mutua Foundation of Madrid).


1. Professionals of the Personalized Pharmacotherapy Unit teach Biology in the Degree of Nursing at Cardenal Herrera University (CEU).

2. Professionals of the Personalized Pharmacotherapy Unit collaborate since 2009 in the teaching of "Curso de monitorización de fármacos en la práctica clínica" organized by the University of Salamanca in collaboration with the General University Hospital of Salamanca and aimed at FIR residents.

3. Professionals from the Personalized Pharmacotherapy Unit have collaborated since 2007 in the teaching of ""Máster en Investigación Clínica"" organized by Medical Practice Group (MPG) in collaboration with the Camilo José Cela University of Madrid.

4.Master's Degree in Multidisciplinary Oncology at the Catholic University of San Antonio, Murcia (UCAM). 90 credits taught in 2 years. directed to graduates in Medicine, who have completed their postgraduate training in any specialty related to the diagnosis and treatment of cancer. Number of new places offered: 30 in the 2013-2014 academic year and 30 in the 2014-2015 academic year.